Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ekso Bionics Holdings (EKSO) over the last 9 years, with Q3 2025 value amounting to $115000.0.

  • Ekso Bionics Holdings' Gains from Investment Securities changed N/A to $115000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $115000.0, marking a year-over-year change of. This contributed to the annual value of -$134000.0 for FY2021, which is 13928.57% down from last year.
  • As of Q3 2025, Ekso Bionics Holdings' Gains from Investment Securities stood at $115000.0.
  • In the past 5 years, Ekso Bionics Holdings' Gains from Investment Securities registered a high of $873000.0 during Q3 2023, and its lowest value of -$131000.0 during Q4 2021.
  • In the last 3 years, Ekso Bionics Holdings' Gains from Investment Securities had a median value of $121500.0 in 2025 and averaged $246250.0.
  • Over the last 5 years, Ekso Bionics Holdings' Gains from Investment Securities had its largest YoY gain of 1300000.0% in 2021, and its largest YoY loss of 1300000.0% in 2021.
  • Over the past 3 years, Ekso Bionics Holdings' Gains from Investment Securities (Quarter) stood at -$131000.0 in 2021, then soared by 766.41% to $873000.0 in 2023, then tumbled by 86.83% to $115000.0 in 2025.
  • Its Gains from Investment Securities was $115000.0 in Q3 2025, compared to $128000.0 in Q2 2025 and $873000.0 in Q3 2023.